Interestingly, LMTK2 negatively regulates AR expression in prostate cancer cells and decreased expression of LMTK2 has been observed in prostate cancer [21], indicating that the regulatory mechanisms between AR and LMTK2 in RCC and prostate cancer may be different. This evidence concerns the gene LMTK2 and renal cell carcinoma.